Originally Posted by
jordan23collecta
Originally Posted by
nicefro
I think CTIC holders are pretty screwed, they waited until 0130 yesterday to release the news in advance of a 3 day weekend. #@!#, #@!#, #@!#.
theres gonna be sellers galore tuesday.
basically. I'm glad I got out when I did, incase anyone didnt see this:
FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
Saturday 09/05/2009 1:30 AM ET - Pr Newswire
[h2]Related Companies[/h2]
Symbol | Last | %Chg |
CTIC | 1.49 | -2.61% |
As of 4:00 PM ET 9/4/09
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA:
CTIC) announced today that the U.S. Food and Drug Administration (
FDA) has notified CTI that a Prescription Drug User Fee Act (
PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (
NHL). Pixantrone has fast track designation for the relapsed / refractory aggressive NHL application.
"The 18 month follow up PIX 301 pivotal trial data continues to demonstrate further improvement in primary and secondary endpoints including Complete Remission / Complete Remission unconfirmed(CR/CRu), Progression Free Survival (
PFS) and Overall Survival over standard chemotherapy. We look forward to providing the four month safety and efficacy update to the FDA and working with them toward potential approval," said James A. Bianco, M.D., Chief Executive Officer of CTI.
Based on the user fee goal date, if pixantrone is approved, CTI estimates that pixantrone could be available to patients in the U.S. early in the second quarter of 2010.
About Pixantrone
Pixantrone (BBR 277
, is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns.
-J23C